Which of the following is reportable to the SEER Program for cases diagnosed in 2025?

The SEER (Surveillance, Epidemiology, and End Results) Program focuses on collecting and reporting data on specific types of cancers and certain precancerous conditions. Each year, the list of reportable conditions can change based on updates from relevant health organizations and cancer registries.

In this case, a cavernous sinus hemangioma is a type of vascular tumor that can be associated with certain neurological symptoms but is generally not considered a malignant neoplasm. However, the SEER Program specifically includes certain benign tumors and specific precancerous conditions that have potential clinical significance in cancer epidemiology.

Cavernous sinus hemangiomas may be reportable due to their location and association with complications that could lead to more serious conditions, such as compression of vital structures. This makes it important to track their incidence in the population, even though they are benign.

In contrast, the other options listed are generally not reportable to the SEER Program, as they do not meet the criteria for malignant neoplasms or significant precursors that necessitate statewide or national tracking. Venous angiomas and neurofibromatosis type 1 do not generally fall under the categories of conditions that SEER captures due to their generally benign nature and lack of direct